Benzinga · Sep 23, 2026
HC Wainwright & Co. Reiterates Buy on Enanta Pharma, Maintains $20 Price Target
HC Wainwright & Co. analyst Brandon Folkes reiterates Enanta Pharma (NASDAQ:ENTA) with a Buy and maintains $20 price target.
NASDAQ · ENTA
Enanta Pharmaceuticals, Inc.
Healthcare · Biotechnology
$12.37
Up+$0.20 (+1.64%)
Updated Oct 8, 2026, 2:15 AM
SID Score
4.0/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 301.87M
- P/E ratio
- -3.69
- Dividend yield
- 0.00%
- 52-week range
- $10.20 – $17.15
- Volume
- 191.67K
- Avg. volume
- 750.44K
Price performance · ENTA
ENTA price history
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 7, 2026
ENTA closed at $12.37 after 21 trading sessions, down 6.57% for the selected period.
- Last close
- $12.37
- Period change
- -6.57%
- Period low
- $11.88
- Period high
- $13.24
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 7, 2026 | $12.09 | $12.57 | $12.05 | $12.37 | 191.67K |
| Oct 6, 2026 | $12.66 | $12.66 | $11.97 | $12.17 | 271.7K |
| Oct 5, 2026 | $12.95 | $13.025 | $12.47 | $12.60 | 218.88K |
| Oct 2, 2026 | $13.20 | $13.21 | $12.58 | $12.96 | 748K |
| Oct 1, 2026 | $13.08 | $13.45 | $12.83 | $12.84 | 331.49K |
| Sep 30, 2026 | $12.67 | $13.41 | $12.44 | $13.18 | 425.88K |
| Sep 29, 2026 | $12.62 | $12.85 | $12.43 | $12.64 | 322.82K |
| Sep 28, 2026 | $11.88 | $12.68 | $11.69 | $12.615 | 349.33K |
| Sep 25, 2026 | $11.99 | $12.00 | $11.64 | $11.88 | 217.32K |
| Sep 24, 2026 | $11.94 | $12.015 | $11.67 | $12.00 | 206.24K |
| Sep 23, 2026 | $12.33 | $12.33 | $11.8727 | $11.95 | 206.32K |
| Sep 22, 2026 | $12.24 | $12.47 | $12.03 | $12.42 | 164.65K |
| Sep 21, 2026 | $12.28 | $12.28 | $11.935 | $12.11 | 217.21K |
| Sep 18, 2026 | $12.49 | $12.605 | $12.19 | $12.20 | 428.25K |
| Sep 17, 2026 | $12.67 | $12.84 | $12.485 | $12.52 | 277.68K |
| Sep 16, 2026 | $12.33 | $12.92 | $12.33 | $12.70 | 267.53K |
| Sep 15, 2026 | $13.07 | $13.07 | $12.16 | $12.29 | 284.88K |
| Sep 14, 2026 | $12.81 | $13.13 | $12.79 | $13.12 | 280.24K |
| Sep 11, 2026 | $12.83 | $13.04 | $12.59 | $12.96 | 289.14K |
| Sep 10, 2026 | $13.09 | $13.21 | $12.44 | $12.70 | 312.79K |
| Sep 9, 2026 | $13.50 | $13.51 | $13.09 | $13.24 | 192.95K |
Latest ENTA news
The latest Smart Investors Daily articles mentioning ENTA.
Stock researchCompany · Overview
Company
Market Activity
Research & News
ENTA research
Overview
Company profile and research snapshot.
Company profile
Enanta Pharmaceuticals Inc is a biotechnology company that uses a chemistry-based drug discovery approach to develop small-molecule candidates for virology and immunology applications. It focuses on Virology and Immunology. Its active development programs in virology are focused on respiratory syncytial virus, or RSV, and SARS-CoV-2, and Hepatitis B virus. In immunology, the company is engaged in designing and developing potent and selective, oral small molecule inhibitors for the treatment of type 2 inflammatory disease. The company has collaborated with AbbVie, which markets its protease inhibitor paritaprevir, with additional inhibitors in development. The company generates the majority revenue in the form of royalty revenue.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $20.00
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 23, 2026 | HC Wainwright & Co. | Buy | — |
| Jun 23, 2026 | HC Wainwright & Co. | Buy | — |
| Feb 10, 2026 | HC Wainwright & Co. | Buy | — |
| Jan 9, 2026 | HC Wainwright & Co. | Buy | — |
| Nov 14, 2025 | JP Morgan | Overweight | — |
News briefing
No generated briefing is available yet.
Yahoo · Sep 1, 2026
Enanta Pharmaceuticals to Participate in September Investor Conferences
WATERTOWN, Mass., September 01, 2026--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases, today announced that members of management will participate in two investor conferences in September:
Benzinga · Aug 10, 2026
Enanta Pharma Q3 EPS $(0.67) Misses $(0.54) Estimate, Sales $14.359M Miss $16.796M Estimate
Enanta Pharma (NASDAQ:ENTA) reported quarterly losses of $(0.67) per share which missed the analyst consensus estimate of $(0.54) by 26.42 percent. This is a 21.18 percent increase over losses of $(0.85) per share from
Benzinga · Jul 2, 2026
Enanta Pharmaceuticals Enters Open Market Sale Agreement With Jefferies; May Offer And Sell Up To $75M Of Common Stock Through Jefferies
-SEC Filing
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
